Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis

Launched by GUANG'ANMEN HOSPITAL OF CHINA ACADEMY OF CHINESE MEDICAL SCIENCES · Apr 9, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of electroacupuncture, a treatment that uses electrical stimulation to improve symptoms, for women experiencing moderate to severe menstrual pain (dysmenorrhea) caused by a condition called adenomyosis. The goal is to see if this method is safe and effective in reducing pain for those who have been suffering for at least three menstrual cycles.

To participate in this study, women aged between 18 and 50 who have been diagnosed with dysmenorrhea due to adenomyosis may be eligible. Candidates should have experienced significant pain during their periods and should not have used other medications or therapies for this condition for at least one month before joining the trial. Participants can expect to receive electroacupuncture treatment and will be carefully monitored throughout the study. It’s important to note that women with certain medical conditions, previous surgeries related to endometriosis, or those who are pregnant or breastfeeding cannot participate.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Meeting the diagnosis criteria of dysmenorrhea secondary to adenomyosis.
• • Female patients aged between 18 and 50.
• • Dysmenorrhea lasting for 3 consecutive menstrual cycles or more.
• • At least three consecutive menstrual cycles with an interval of 24 to 38 days, differing by less than 7 days, and menstrual periods lasting 2 to 8 days before screening.
• • At least 2 days of worst pain score ≥4 on Numerical Rating Scale during the screening period.
• • Having not used medications, other than rescue medicine, or therapies for dysmenorrhea secondary to adenomyosis for at least 1 month before randomization, and consenting not to use throughout the process of the research.
• • Volunteering to participate the trial and signing written informed consent.
• Exclusion Criteria:
• • Diagnosed with Endometriosis or having a history of endometriosis-related surgery
• • Currently taking hormonal medications, including: a.use of GnRH agonists within 6 months before the screening period; b. use of progestins or danazol and other long-acting hormones within 3 months before the screening period; c. use of oral contraceptive-like short-acting hormones within one month before the screening period;
• • Having clinically significant gynecologic condition such as clinically significant endometrial pathology, persistent complex ovarian cyst larger than 3 cm or simple ovarian cyst larger than 5 cm, or single fibroid 4 cm or larger or more than 4 fibroids measuring at least 2 cm or symptomatic submucosal fibroid of any size.
• • having an IUD.
• • HB \< 90G/L.
• • Having any other chronic pain syndrome that required chronic analgesic or other chronic therapy.
• • Having a current history of undiagnosed abnormal genital bleeding.
• • Malignant tumors (including the reproductive system and other systems).
• • Combined with severe diseases in the cardiac, respiratory, renal, liver, and hematopoietic systems, psychiatric disorder and/or cognitive disorders.
• • Pregnant, breast feeding, planning a pregnancy within the next 7 months.